← Leaderboards
George E Wright
Glsynthesis, Inc.
$12,214,325
Attributed
$12,364,325
Total exposure
11
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–12$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$12,364,325 · 11
By mechanism
R44$10,948,241 · 6
R43$1,416,084 · 5
Top collaborators
- Sofya Dvoskin1 shared
Others in their field
Top investigators on “Drug Screening /Evaluation”
- Fred M Gordin · Social And Scientific Systems, Inc.$68,001,399
- John C S Breitner · Johns Hopkins University$33,065,187
- Philip J Disaia · University Of California Irvine$21,551,991
- George R Painter · Chimerix, Inc.$19,230,662
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Stephen J Durako · Westat, Inc.$15,048,684
Research focus
Drug Screening /EvaluationAntibioticsDrug Design /Synthesis /ProductionInhibitor/AntagonistPharmaceutical PreparationsInfectionAnti-Bacterial AgentsInvestigational New Drug ApplicationPreclinical StudyDna-Directed Dna PolymeraseToxicokineticsPathologyPre-ClinicalIn VitroToxicologyIn VivoClinical TrialsGuanineStaphylococcus AureusPharmacokineticsBaseEnterococcusDna Directed Dna PolymeraseAnalog
Grant awards (21)
Preclinical development of a novel antibacterial for Clostridium difficile diseas$1,415,514
R44 · FY2012 · AI · contact PI
Oral prodrug of a novel antiviral that blocks neuronal reactivation of HSV$300,000
R43 · FY2012 · AI
Preclinical development of a novel antibacterial for Clostridium difficile diseas$935,484
R44 · FY2011 · AI · contact PI
Preclinical development of a novel antibacterial for Clostridium difficile diseas$620,114
R44 · FY2010 · AI · contact PI
Analogs of GTP as novel inhibitors of bacterial c-di-GMP-synthesizing enzymes$299,848
R43 · FY2010 · AI · contact PI
Hybrid Molecules Designed to Enhance Antibiotic Activity$39,858
R44 · FY2009 · AI · contact PI
Hybrid Molecules Designed to Enhance Antibiotic Activity$967,036
R44 · FY2008 · AI · contact PI
Hybrid Molecules Designed to Enhance Antibiotic Activity$939,605
R44 · FY2007 · AI · contact PI
Hybrid Molecules Designed to Enhance Antibiotic Activity$938,275
R44 · FY2006 · AI · contact PI
DNA Polymerase IIIe, A New Antibiotic Target$907,102
R44 · FY2006 · AI · contact PI
DNA Polymerase IIIe, A New Antibiotic Target$944,079
R44 · FY2005 · AI
Fluorosome Technique for Drug Permeability Studies$444,404
R44 · FY2005 · RR
High Throughput Membrane-Water Partition Coefficients$255,352
R43 · FY2005 · GM
Fluorosome Technique for Drug Permeability Studies$489,125
R44 · FY2004 · RR
Hybrid Molecules Designed to Enhance Antibiotic Activity$477,327
R44 · FY2003 · GM
Antiviral Drugs for Treatment of Herpes B Infections$253,746
R43 · FY2003 · AI
Hybrid Molecules Designed to Enhance Antibiotic Activity$499,799
R44 · FY2002 · GM
DNA Polymerase IIIE, A New Antibiotic Target$307,138
R43 · FY2002 · AI
DRUGS TO PREVENT RECURRENT HERPESVIRUS INFECTIONS$416,669
R44 · FY2001 · AI
GRAM+ ANTIMICROBIALS TARGETED TO DNA POLYMERASE III$549,815
R44 · FY2000 · AI
DRUGS TO PREVENT RECURRENT HERPESVIRUS INFECTIONS$364,035
R44 · FY2000 · AI